Recruitment Status: Not Yet Recruiting
1. Study of Arikace in People with CF with Chronic Lung Infection Due to Pseudomonas Aeruginosa
Liposomal amikacin for inhalation (Arikace) was developed as a possible treatment for chronic infection due to Pseudomonas aeruginosa in people with CF. The purpose of this double-blind, placebo controlled study is to determine whether Arikace is effective in treating chronic lung infections caused by Pseudomonas aeruginosa in people with CF.
Study Drugs: Arikace
Study Ages: >= 6 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Not applicable
FEV1% Status: >= 25 Percent Predicted
Trial Results Not Yet Available
 
2. Long term study of Arikace in people with CF with Chronic Pseudomonas Aeruginosa Lung Infection
This study will look at the long term safety and tolerability of Arikace in people with Cystic Fibrosis for up to approximately 2 years.
Study Drugs: Arikace
Study Ages: >= 6 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Not applicable
FEV1% Status: >= 25 Percent Predicted
Trial Results Not Yet Available
 
3. Inhaled Mannitol in Adults with Cystic Fibrosis
This trial will look at how well the drug mannitol works and how safe it is in adults with cystic fibrosis. The trial will last 6 months. It is for people with CF ages 18 and older.
Study Drugs: Bronchitol
Study Ages: >= 18 Years
Type of Therapy: Restore Airway Surface Liquid
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: 40 - 90 Percent Predicted
Trial Results Not Yet Available
 
Recruitment Status: Recruiting
4. Practical Two-Step Screening for Cystic Fibrosis Related Diabetes and prediabetes
This is a multi-center interventional study to determine if a two step strategy could be used to screen for CFRD and prediabetes in people with CF ages 10 years and older.
Study Ages: >= 10 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= Percent Predicted
Trial Results Not Yet Available
 
5. Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered Twice a Day Cycled
This is a phase 4 multi-center study that aims to provide effectiveness and safety data on two dosing schedules of Tobramycin Inhalation Powder (TIP) for the treatment of pulmonary Pseudomonas aeruginosa in patients with cystic fibrosis.
Study Drugs: Tobramycin Inhalation Powder
Study Ages: >= 6 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Negative
FEV1% Status: 25 - 80 Percent Predicted
Trial Results Not Yet Available
 
6. Study of Inhaled TOBI for the Treatment of Early Infections of Pseudomonas Aeruginosa in children with CF ages 3 Months to less than 7 Years
This is a phase 4 interventional study that will look at the effectiveness of inhaled TOBI treatment for early infections of Pseudomonas aeruginosa in pediatric patients with cystic fibrosis.
Study Drugs: TOBI
Study Ages: 3 Months - 7 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
7. Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis Extension Study
The purpose of this extension study is to collect additional safety data from patients taking TIP who have completed the core study "Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis".
Study Drugs: Tobramycin Inhalation Powder
Study Ages: >= 6 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Negative
FEV1% Status: 25 - 75 Percent Predicted
Trial Results Not Yet Available
 
8. OPTIMIZE
This placebo-controlled, double-blind, multi-center trial will compare the effects of treatment with tobramcyin solution for inhalation with and without azithromycin in people with CF, age 6 months to 18 years, who have their first isolation of Pseudomonas aeruginosa from a respiratory culture.
Study Drugs: Azithromycin
Study Ages: 6 Months - 18 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Negative
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
9. AeroVanc for the treatment of MRSA in people with CF
This study will look to see if AeroVanc treatment is safe and effective at reducing MRSA bacteria in the lungs of cystic fibrosis patients. This study is for people ages 12 and older.
Study Drugs: Inhaled Vancomycin
Study Ages: >= 12 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Not applicable
B Cepacia Status: Negative
FEV1% Status: 30 - 100 Percent Predicted
Trial Results Not Yet Available
 
10. Early Treatment of New Onset of Methicillan Resistant Staphylococcus Aureus (MRSA) Growth in Respiratory Culture
This study will evaluate an early eradication protocol to eliminate Methicillan Resistant Staphylococcus Aureus (MRSA) from the lungs of people with CF who grow this bacteria for the first time in a respiratory culture.
Study Drugs: Multiple systemic antibiotics
Study Ages: 4 Years - 45 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 30 Percent Predicted
Trial Results Not Yet Available
 
11. Persistent Methicillan Resistant Staphylococcus Aureus (MRSA) Growth in Respiratory Culture
This study will look at the safety and effectiveness of a 28-day course of vancomycin for inhalation in getting rid of the bacteria, Methicillan Resistant Staphylococcus Aureus (MRSA), from the respiratory tract of people with CF and persistent MRSA infection.
Study Drugs: Multiple systemic antibiotics
Study Ages: >= 12 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Not applicable
B Cepacia Status: Negative
FEV1% Status: >= 30 Percent Predicted
Trial Results Not Yet Available
 
12. AquADEKs-2 - Effects of an Antioxidant-Enriched Multivitamin on Inflammation and Oxidative Stress in people with CF
This multi-center trial will look at the effects of an anti-oxidant enriched multivitamin supplement on inflammation and oxidative stress in people with CF 10 years of age and older.
Study Drugs: AquADEKs-2
Study Ages: >= 10 Years
Type of Therapy: Anti-Inflammatory
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: 40 - 100 Percent Predicted
Trial Results Not Yet Available
 
13. KB001-A in People with CF and Pseudomonas Aeruginosa
This study will look to see if the use of KB001A in people with CF who have Pseudomonas aeruginosa (PA) will delay the need for antibiotic drugs. This study is for people ages 12 and above.
Study Drugs: KB001-A
Study Ages: 12 Years - 50 Years
Type of Therapy: Anti-Inflammatory
Pseudomonas Status: Positive
B Cepacia Status: Negative
FEV1% Status: 40 - 100 Percent Predicted
Trial Results Not Yet Available
 
14. Vertex 661/770 in People with Cystic Fibrosis and F508del-CFTR mutation
The study will evaluate safety and efficacy of VX-661 in combination with ivacaftor when administered for 12 weeks.
Study Drugs: VX-661/VX-770
Study Ages: >= 18 Years
Type of Therapy: CFTR Modulation
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: 40 - 90 Percent Predicted
Trial Results Not Yet Available
 
15. Burlulipase in People with CF and Pancreatic Insufficiency
This is a Phase 2 multi-center, randomized, double-blind trial looking at the effectiveness of burlulipase in people with CF and pancreatic insufficiency who are ages 12 years and above.
Study Drugs: Burlulipase/NM-BL-101
Study Ages: >= 12 Years
Type of Therapy: Nutritional-GI Therapies
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
16. Vitamin D for enhancing the immune system in people with CF
This multi-center trial will look at the effect of a one time high-dose vitamin D to rapidly correct vitamin D deficiency in people with CF who are over 16 years of age admitted to the hospital for pulmonary exacerbation.
Study Drugs: Vitamin D
Study Ages: >= 16 Years
Type of Therapy: Nutritional-GI Therapies
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 20 Percent Predicted
Trial Results Not Yet Available
 
17. Home Monitoring of Lung Function
This study will look at the monitoring lung function and lung symptoms at home.
Study Ages: >= 14 Years
Type of Therapy: Other
Pseudomonas Status: Not applicable
B Cepacia Status: Negative
FEV1% Status: >= 26 Percent Predicted
Trial Results Not Yet Available
 
18. Nasal Insufflation in Cystic Fibrosis
This is a single center interventional study to determine if a new treatment can help people with CF breathe easier and gain weight. It is for ages 7 and above.
Study Drugs: High Flow Nasal Insufflation/HFNI
Study Ages: 7 Years - 80 Years
Type of Therapy: Other
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
19. Sweat Chloride Comparison Project
This is a single center interventional study to compare methods for accurate and reproducible sweat chloride collection in pediatric patients.
Study Drugs: Gibson and Cooke technique
Study Ages: 1 Days - 17 Years
Type of Therapy: Other
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
Recruitment Status: Recruiting Completed
20. Aztreonam for Inhalation Solution (AZLI) taken in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas aeruginosa lung infections in people with CF
This study looked to see if altering between two different types of antibiotics could help to improve the treatment of Pseudomonas aeruginosa in people with CF ages 6 years and older.
Study Drugs: Cayston
Study Ages: >= 6 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Negative
FEV1% Status: 25 - 75 Percent Predicted
Trial Results Not Yet Available
 
21. Arikace for Nontuberculous Mycobacteria (NTM)
The purpose of this study was to determine whether Arikace is effective in treating recalcitrant nontuberculous mycobacterial lung disease. The safety and tolerability of Arikace in this patient population was also assessed.
Study Drugs: Arikace
Study Ages: 12 Years - 75 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
22. Vertex Lumacaftor (VX-809) and Ivacaftor in Children with CF aged 6 to 11 years and have two copies of the delF508 CFTR mutation
This study looked at the pharmacokinetics and safety of lumacaftor (VX 809) in combination with ivacaftor in children with cystic fibrosis aged 6 to 11 years who have the F508del-mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Study Drugs: VX-809/VX-770
Study Ages: 6 Years - 11 Years
Type of Therapy: CFTR Modulation
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
23. Vertex Lumacaftor (VX-809) and ivacaftor in people with CF who are aged 12 years and have two copies of the delF508 CFTR mutation (TRAFFIC)(103)
This is the first of two nearly identical Phase 3 trials looking at the safety and effectiveness of the study drug VX 809 in combination with ivacaftor in people with CF who are aged 12 years and older and have two copies of the F508del-CFTR mutation.
Study Drugs: VX-809/VX-770
Study Ages: >= 12 Years
Type of Therapy: CFTR Modulation
Pseudomonas Status: Not applicable
B Cepacia Status: Negative
FEV1% Status: >= 40 Percent Predicted
Trial Results Not Yet Available
 
24. Vertex Lumacaftor (VX-809) and Ivacaftor in People with CF aged 12 years and older and have two copies of the delF508 CFTR mutation (TRANSPORT)(104)
This is the second of two nearly identical Phase 3 trials looking at the safety and effectiveness of the study drug VX 809 in combination with Kalydeco in people with CF who are aged 12 years and older and have two copies of the F508del-CFTR mutation.
Study Drugs: VX-809/VX-770
Study Ages: >= 12 Years
Type of Therapy: CFTR Modulation
Pseudomonas Status: Not applicable
B Cepacia Status: Negative
FEV1% Status: >= 40 Percent Predicted
Trial Results Not Yet Available
 
25. Ivacaftor Open Label Follow on Study in People with CF who have a Non-G551D CFTR Mutation (112)
This trial is looking at the safety of long term ivacaftor treatment in people with CF who have a non-G551D CFTR mutation.
Study Drugs: Kalydeco
Study Ages: >= 6 Years
Type of Therapy: CFTR Modulation
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
26. Ivacaftor in People with CF age 2 to 5 years with a CFTR Gating Mutation (VX 770-108)
This study will look at the safety, pharmacokinetics (PK), and pharmacodynamics (PD), of ivacaftor in children with CF who are 2 through 5 years of age and have a CFTR gating mutation in at least 1 allele.
Study Drugs: Kalydeco
Study Ages: 2 Years - 5 Years
Type of Therapy: CFTR Modulation
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
27. Vertex 809/770 (102) in People with Cystic Fibrosis and F508del-CFTR mutation
This study looked at the safety and effectiveness of VX 809 and VX770 when given in combination to people with CF who have either one or two copies of the F508del-CFTR mutation.
Study Drugs: VX-809/VX-770
Study Ages: >= 18 Years
Type of Therapy: CFTR Modulation
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 40 Percent Predicted
Trial Results Not Yet Available
 
28. Ataluren (PTC 124) Open Label Extension Study in Cystic Fibrosis
This study is a Phase 3 extension trial that evaluated the long-term safety of ataluren (PTC124) in adult and pediatric patients with nonsense mutation CF, as determined by adverse events and laboratory abnormalities.
Study Drugs: PTC124
Study Ages: >= 6 Years
Type of Therapy: CFTR Modulation
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: 40 - 90 Percent Predicted
Trial Results Not Yet Available
 
29. Effects of Nutrition and Lung Disease on Growth in Preschoolers with CF
The purpose of this study is to examine the relationship between a newly developed nutritional method, patient growth, and lung disease.
Study Ages: 2 Years - 6 Years
Type of Therapy: Other
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
Recruitment Status: Trial Completed
30. Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis
This study will assess the long term safety for the use of tobramycin inhalation powder (TIP) in people with cystic fibrosis who are 6 years of age and older and who have a chronic pulmonary infection with Pseudomonas Aeruginosa.
Study Drugs: Tobramycin Inhalation Powder
Study Ages: >= 6 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Negative
FEV1% Status: 25 - 75 Percent Predicted
Trial Results Not Yet Available
 
31. Aztreonam Inhalation Solution (AZLI) Safety Study in Children with CF and Chronic Pseudomonas Aeruginosa
This study looked at the safety of Aztreonam Inhalation Solution (AZLI) given three times daily for three 28 day on/ 28 day off cycles in children < 13 years of age with Cystic Fibrosis (CF) and chronic Pseudomonas Aeruginosa (PA) infection in the lower airways.
Study Drugs: Cayston
Study Ages: 1 Days - 12 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Negative
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
32. Aztreonam (AZLI) in Infants and Children with CF and New Onset Pseudomonas Aeruginosa
This an open-label, multi-center trial looking at the effectiveness of Aztreonam Inhalation Solution given to infants and children with CF, age 3 months to less than 18 years, who have a newly detected Pseudomonas Aeruginosa lung infection based upon respiratory culture results.
Study Drugs: Cayston
Study Ages: 3 Months - 17 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Negative
FEV1% Status: >= 90 Percent Predicted
Trial Results Not Yet Available
 
33. Levofloxacin Inhalation Solution (Aeroquin) compared to TOBI in people with Cystic Fibrosis
This study will look at the safety and effectiveness of the study drug, Levofloxacin Inhalation solution, (Aeroquin�) compared to Tobramycin Solution for Inhalation (TOBI®) people with CF that have chronic Pseudomonas aeruginosa lung infection.
Study Drugs: Levofloxacin (Inhaled)
Study Ages: >= 12 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Not applicable
FEV1% Status: 25 - 85 Percent Predicted
Trial Results Not Yet Available
 
34. Levofloxacin Inhalation Solution (Aeroquinâ?¢) compared to placebo in people with Cystic Fibrosis
This trial will study the safety and effectiveness of the aerosolized form of the antibiotic, levofloxacin, (AEROQUINâ?¢) in people with Cystic Fibrosis.
Study Drugs: Levofloxacin (Inhaled)
Study Ages: >= 12 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Not applicable
FEV1% Status: 25 - 85 Percent Predicted
Trial Results Not Yet Available
 
35. Amikacin for Inhalation (Transave)
This study looked at a new way an inhaled antibiotic can be made for people with CF and a positive pseudomonas aeruginosa lung infection.
Study Drugs: Arikace
Study Ages: >= 6 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Negative
FEV1% Status: >= 40 Percent Predicted
Trial Results Exist
 
36. Inhaled Fosfomycin/Tobramycin for People with CF and P. aeruginosa
The purpose of this study is to evaluate the safety and efficacy of 2 dose combinations of fosfomycin/tobramycin for inhalation (FTI), following a 28-day course of Aztreonam for Inhalation (AZLI) in patients with cystic fibrosis and Pseudomonas aeruginosa lung infection.
Study Drugs: Fosfomycin-Tobramycin (Inhaled)
Study Ages: >= 18 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Not applicable
FEV1% Status: 25 - 75 Percent Predicted
Trial Results Exist
 
37. Tobramycin Inhalation Powder Compared to TOBI in People with CF
Study Drugs: Tobramycin Inhalation Powder
Study Ages: >= 6 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Negative
FEV1% Status: 25 - 75 Percent Predicted
Trial Results Exist
 
38. Inhaled Levofloxacin (MP-376) Pediatric Safety Study
This study will look at the safety, tolerability and how the body processes MP-376 Inhalation Solution given to children 6 to 16 years of age with Cystic Fibrosis.
Study Drugs: Levofloxacin (Inhaled)
Study Ages: 6 Years - 16 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: 25 - 95 Percent Predicted
Trial Results Not Yet Available
 
39. Inhaled Levofloxacin (MP-376) in CF Patients with P. aeruginosa (Phase 2 Study)
MP-376 is a form of levofloxacin being developed to be inhaled to control chronic pulmonary infections due to Pseudomonas aeruginosa and other bacteria.
Study Drugs: Levofloxacin (Inhaled)
Study Ages: >= 16 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Negative
FEV1% Status: 25 - 75 Percent Predicted
Trial Results Exist
 
40. Azithromycin in Patients with CF and Culture Negative for Pseudomonas aeruginosa
This study evaluated the effect of azithromycin in children with CF who are not infected with Pseudomonas aeruginosa.
Study Drugs: Azithromycin
Study Ages: 6 Years - 18 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Negative
B Cepacia Status: Negative
FEV1% Status: >= 50 Percent Predicted
Trial Results Exist
 
41. Safety Study of Azithromycin in Cystic Fibrosis Patients Negative for P. aeruginosa
This study was an open-label extension study of the Azithromycin study in adolescents and children with CF who were not infected with P. aeruginosa. This study provided addiitonal information regarding the safety of longer term treatment.
Study Drugs: Azithromycin
Study Ages: 6 Years - 18 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Not applicable
B Cepacia Status: Negative
FEV1% Status: >= 30 Percent Predicted
Trial Results Exist
 
42. Early Pseudomonas Infection Control (EPIC)
This study examined how often antibiotics should be administered to produce the greatest reduction in respiratory infections and pulmonary exacerbations.
Study Drugs: TOBI
Study Ages: 1 Years - 12 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Exist
 
43. Inhaled Ciprofloxacin for People with CF and Pseudomonas aeruginosa
This study will compare the change in FEV1 from baseline to Day 28 between Cipro Inhale-treated and placebo-treated subjects.
Study Drugs: Ciprofloxacin DPI
Study Ages: >= 12 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Negative
FEV1% Status: 35 - 75 Percent Predicted
Trial Results Not Yet Available
 
44. Biomarker of Pulmonary Exacerbation in Patients with CF
This study examined if biomarkers indicate progression of CF lung disease.
Study Drugs: Multiple systemic antibiotics
Study Ages: >= 10 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
45. Antibiotic Susceptibility Testing Using the Standard vs. the Biofilm Method
This study compared the effectiveness of selecting antibiotic treatments through either a standard laboratory test or a new testing method.
Study Drugs: Multiple systemic antibiotics
Study Ages: >= 18 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Negative
FEV1% Status: >= 1 Percent Predicted
Trial Results Exist
 
46. Inhaled Aztreonam Vs. TOBI in People with CF and P. aeruginosa
The purpose of this study was to look at the safey and effectiveness of Aztreonam for Inhalation Solution versus Tobramycin Nebulizer Solution in adult and pediatric patients with CF and pulmonary Pseudomonas Aeruginosa.
Study Drugs: Cayston
Study Ages: >= 6 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Negative
FEV1% Status: 1 - 75 Percent Predicted
Trial Results Exist
 
47. AZLI (Inhaled Aztreonam) for People with Cystic Fibrosis and Chronic Burkholderia Infection
This study looked at the safety and effectiveness of Aztreonam Inhalation Solution in people with Cystic Fibrosis and chronic burkholderia cepacia infection.
Study Drugs: Cayston
Study Ages: >= 6 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Not applicable
B Cepacia Status: Positive
FEV1% Status: >= 1 Percent Predicted
Trial Results Exist
 
48. Expanded Access Program for Aztreonam Lysine for Inhalation
Aztreonam Lysine for Inhalation is now available to people with CF who meet specific criteria through an expanded access program.
Study Drugs: Cayston
Study Ages: >= 6 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Negative
FEV1% Status: 1 - 50 Percent Predicted
Trial Results Not Yet Available
 
49. Long-term Safety Study of Aztreonam Lysinate in CF Patients with P. aeruginosa (AIR-CF3)
The purpose of this study was to evaluate the safety of an inhaled antibiotic, aztreonam, in CF patients who have respiratory infections caused by the Pseudomonas aeruginosa bacteria
Study Drugs: Cayston
Study Ages: >= 6 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Not applicable
FEV1% Status: 25 - 75 Percent Predicted
Trial Results Exist
 
50. Aztreonam Lysinate for Inhalation in Individuals who Utilize Inhaled Tobramycin Frequently (AIR-CF2)
The purpose of this study was to evaluate the safety and efficacy of an inhaled formulation of aztreonam lysine in CF patients who have respiratory infections caused by the Pseudomonas aeruginosa bacteria.
Study Drugs: Cayston
Study Ages: >= 6 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Negative
FEV1% Status: 25 - 75 Percent Predicted
Trial Results Exist
 
51. Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients with P. aeruginosa (AIR-CF1)
The purpose of this study was to evaluate the safety and efficacy of an inhaled antibiotic, Aztreonam, in CF patients who have respiratory infections caused by the Pseudomonas aeruginosa bacteria.
Study Drugs: Cayston
Study Ages: >= 6 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Negative
FEV1% Status: 25 - 75 Percent Predicted
Trial Results Exist
 
52. Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients with Mild Lung Disease and P. aeruginosa (AIR-CF4)
This study looked at the safety and use of a 28-day treatment with an inhaled antibiotic, aztreonam in CF patients with mild lung disease and positive Pseudomonas aeruginosa culture.
Study Drugs: Cayston
Study Ages: >= 6 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Not applicable
FEV1% Status: >= 75 Percent Predicted
Trial Results Exist
 
53. Inhaled Alpha-1 HC in People with CF
The purpose of this study is to look at the safety and tolerability of 100 mg and 200 mg of inhaled Alpha-1 HC administered once a day for three weeks in people with CF who are age 18 years and older.
Study Drugs: Alpha 1 Anti-Trypsin
Study Ages: >= 18 Years
Type of Therapy: Anti-Inflammatory
Pseudomonas Status: Not applicable
B Cepacia Status: Negative
FEV1% Status: 40 - 90 Percent Predicted
Trial Results Not Yet Available
 
54. Effect of Simvastatin on CF Airway Inflammation
This study examined the safety and efficacy of simvastatin in decreasing inflammation of the respiratory airways in patients with CF.
Study Drugs: Simvastatin
Study Ages: >= 10 Years
Type of Therapy: Anti-Inflammatory
Pseudomonas Status: Not applicable
B Cepacia Status: Negative
FEV1% Status: >= 60 Percent Predicted
Trial Results Exist
 
55. PharmaNAC Phase 2b: N-Acetylcysteine Effects in CF
This study will look at the effects of an investigational product called N-acetylcysteine (NAC) on the basic processes that cause inflammation in CF lung disease.
Study Drugs: N-Acetylcystiene (Oral)
Study Ages: >= 7 Years
Type of Therapy: Anti-Inflammatory
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: 40 - 85 Percent Predicted
Trial Results Not Yet Available
 
56. Safety Study of KB001 in People with CF and Pseudomonas aeruginosa
This study looked at what a single-dose of an investigational drug, KB001, does to Pseudomonas aeruginosa in the CF lung.
Study Drugs: KB001-A
Study Ages: >= 12 Years
Type of Therapy: Anti-Inflammatory
Pseudomonas Status: Positive
B Cepacia Status: Negative
FEV1% Status: >= 40 Percent Predicted
Trial Results Exist
 
57. Single Dose Safety Study of SB-656933 in People with CF
This study will look at the safety and pharmacokinetics of one dose of SB-656933 in people with CF.
Study Drugs: SB-656933
Study Ages: >= 16 Years
Type of Therapy: Anti-Inflammatory
Pseudomonas Status: Not applicable
B Cepacia Status: Negative
FEV1% Status: >= 40 Percent Predicted
Trial Results Not Yet Available
 
58. Multiple Dose Safety Study of SB-656933 in People with Cystic Fibrosis
The purpose of this study was to determine the safety, tolerability and pharmacodynamics of SB656933 in patients that have cystic fibrosis.
Study Drugs: SB-656933
Study Ages: >= 18 Years
Type of Therapy: Anti-Inflammatory
Pseudomonas Status: Not applicable
B Cepacia Status: Negative
FEV1% Status: 40 - 110 Percent Predicted
Trial Results Exist
 
59. Infant Formula Fortified with DHA
The purpose of this study is to see if feeding infants diagnosed with CF through newborn screening with a formula fortified with DHA can slow damage from CF.
Study Drugs: Docosahexaenoic Acid (DHA)
Study Ages: 1 Days - 56 Days
Type of Therapy: Anti-Inflammatory
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
60. VX -770 (104) in People with CF age 12 and older with 2 copies of the F508del-cftr mutation
The purpose of this study is to assess the safety and effectiveness of VX-770 in people with cystic fibrosis (CF) who have two copies of the F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutation for 16 weeks.
Study Drugs: Kalydeco
Study Ages: >= 12 Years
Type of Therapy: CFTR Modulation
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 40 Percent Predicted
Trial Results Exist
 
61. Ivacaftor in People with CF who have a Non G551D Gating Mutation (KONNECTION) (111)
The purpose of this trial is to look at the safety and effectiveness of ivacaftor (trade name Kalydeco) in people with cystic fibrosis (CF) who have a non-G551D cystic fibrosis transmembrane regulator (CFTR) gating mutation (any one of the following CFTR mutations: G178R, G551S, S549N, S549R, G970R, G1244E, S1251N, S1255P, or G1349D).
Study Drugs: Kalydeco
Study Ages: >= 6 Years
Type of Therapy: CFTR Modulation
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: 40 - 105 Percent Predicted
Trial Results Not Yet Available
 
62. Ivacaftor in People with CF who have the R117H-CFTR mutation (KONDUCT)(110)
This study will look at the safety and effectiveness of ivacaftor (Kalydeco) in people with CF who have the R117H-CFTR mutation.
Study Drugs: Kalydeco
Study Ages: >= 6 Years
Type of Therapy: CFTR Modulation
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: 40 - 105 Percent Predicted
Trial Results Not Yet Available
 
63. VX-661 (101) alone and in combination with Ivacaftor in People with Cystic Fibrosis and F508del-CFTR mutation
This Phase 2 trial will look at the safety, effectiveness of VX-661 alone and in combination with ivacaftor in people with CF who have two copies of the F508del-CFTR mutation. Additionally this trial will look at the pharmacological properties of VX-661 in the body - how well the body absorbs, breaks down, and gets rid of VX-661.
Study Drugs: VX-661/VX-770
Study Ages: >= 18 Years
Type of Therapy: CFTR Modulation
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: 40 - 90 Percent Predicted
Trial Results Not Yet Available
 
64. VX-770 (901) Expanded Access Program
People with CF who have at least one copy of the G551D-CFTR mutation and who are in critical medical need and who are not eligible for participation in other Vertex-sponsored studies may be able to receive VX-770 through an expanded access program.
Study Drugs: Kalydeco
Study Ages: >= 6 Years
Type of Therapy: CFTR Modulation
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: 1 - 40 Percent Predicted
Trial Results Not Yet Available
 
65. Vertex 770 - a phase 2 trial evaluating the effect of VX- 770 on Lung Clearance Index (VX 770-106)
This trial will study the effect of VX-770 on lung clearance index in people with CF ages 6 years and older with the G551D mutation and an FEV1 >90%.
Study Drugs: Kalydeco
Study Ages: >= 6 Years
Type of Therapy: CFTR Modulation
Pseudomonas Status: Not applicable
B Cepacia Status: Negative
FEV1% Status: >= 90 Percent Predicted
Trial Results Not Yet Available
 
66. VX-770 in People with CF and G551D Mutation - Open Label Safety Study (PERSIST)
This study will look at the long-term safety of VX-770 in people with CF and the G551D mutation. Subjects will receive VX-770 for 96 weeks during this study.
Study Drugs: Kalydeco
Study Ages: >= 6 Years
Type of Therapy: CFTR Modulation
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
67. Safety Study of VX 809 in People with CF and Homozygous for Delta F508 Gene Mutation
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-809 in subjects with cystic fibrosis who have the delta F508-CFTR gene mutation.
Study Drugs: VX-809
Study Ages: >= 18 Years
Type of Therapy: CFTR Modulation
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 40 Percent Predicted
Trial Results Exist
 
68. Vertex-770 (104) in People with CF with Homozygous Delta F508 Mutation (DISCOVER)
This study looked at the safety and effectiveness of VX-770 in people with Cystic Fibrosis (CF) age 12 years and older, with homozygous Delta F508 mutation.
Study Drugs: Kalydeco
Study Ages: >= 12 Years
Type of Therapy: CFTR Modulation
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 40 Percent Predicted
Trial Results Exist
 
69. Vertex 770 in Children with CF and the G551 Mutation (ENVISION)
This study looked at the safety and effectiveness of VX-770 in people with CF aged 6 to 11 years with the G551D mutation.
Study Drugs: Kalydeco
Study Ages: 6 Years - 11 Years
Type of Therapy: CFTR Modulation
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: 40 - 90 Percent Predicted
Trial Results Exist
 
70. Vertex-770 and the G551D mutation (STRIVE)
This study looked at the effectiveness of VX-770 in people with CF and the G551D mutation by evaluating an absolute change from baseline in % predicted FEV1 through week 24 and safety over a longer treatment period than previously studied.
Study Drugs: Kalydeco
Study Ages: >= 12 Years
Type of Therapy: CFTR Modulation
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: 40 - 90 Percent Predicted
Trial Results Exist
 
71. VX-770 Phase 2 study in People with CF and Genotype 551D
This Phase 2 clinical trial looked at the safety and tolerability of VX-770 in people with CF and the genotype G551D.
Study Drugs: Kalydeco
Study Ages: >= 18 Years
Type of Therapy: CFTR Modulation
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 40 Percent Predicted
Trial Results Exist
 
72. Ataluren (PTC 124) in Cystic Fibrosis
This study was a Phase 3 trial that evaluated the clinical benefit of Ataluren (PTC 124) in adult and pediatric patients with CF due to a nonsense mutation.
Study Drugs: PTC124
Study Ages: >= 6 Years
Type of Therapy: CFTR Modulation
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: 40 - 90 Percent Predicted
Trial Results Exist
 
73. PULMOZYME delivered by the eRapid Nebulizer
This is a phase 4 multi-center, randomized, open-label trial looking at the safety and effectiveness of Pulmozyme delivered by the eRapid nebulizer system.
Study Drugs: Pulmozyme
Study Ages: >= 6 Years
Type of Therapy: Mucus Alteration
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 40 Percent Predicted
Trial Results Not Yet Available
 
74. Effect of Pulmozyme® Withdrawal on Exercise Tolerance in People with Cystic Fibrosis
This study looks at the ability to do exercise, pulmonary function tests and other effects in people with CF when Pulmozyme® is withdrawn for 2 weeks.
Study Drugs: Pulmozyme
Study Ages: >= 14 Years
Type of Therapy: Mucus Alteration
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
75. Pulmozyme in 3-5 Year Old Children with CF
This study looked at the effect of Pulmozyme on preschool aged (3-5 year old) children.
Study Drugs: Pulmozyme
Study Ages: 3 Years - 5 Years
Type of Therapy: Mucus Alteration
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Exist
 
76. Study of delayed released pancrelipase capsules in people with CF and pancreatic insufficiency
This study will assess the effect of pancrelipase delayed release 24,000 unit capsules on fat and nitrogen absorption in people with Cystic Fibrosis and pancreatic insufficiency.
Study Drugs: Creon
Study Ages: >= 12 Years
Type of Therapy: Nutritional-GI Therapies
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Exist
 
77. Study of Pancrease MT Capsules in People with CF and Pancreatic Insufficiency
The purpose of this study was to assess the effectiveness and safety of oral pancrelipase MT in the treatment of adult and pediatric/adolescent cystic fibrosis (CF) patients with clinical symptoms of exocrine pancreatic insufficiency (EPI).
Study Drugs: Pancrease MT
Study Ages: 7 Years - 60 Years
Type of Therapy: Nutritional-GI Therapies
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Exist
 
78. Pancrecarb MS-16 in children and adults with CF
The purpose of this study was to determine if PANCRECARB® MS-16 (pancrelipase) was safe and effective in reducing steatorrhea in children and adults with cystic fibrosis and pancreatic insufficiency
Study Drugs: Pancrecarb MS-16
Study Ages: >= 7 Years
Type of Therapy: Nutritional-GI Therapies
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Exist
 
79. Efficacy and Safety of Pancrelipase Delayed Release Capsules in Young Children with CF
This study will look at the effect a new formulation of an enzyme replacement therapy will have on fat absorption in young children with CF and pancreatic insufficiency.
Study Drugs: Creon
Study Ages: 1 Months - 6 Years
Type of Therapy: Nutritional-GI Therapies
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
80. Safety and Effectiveness of the Eurand Pancreatic Enzyme Supplement in People with CF
In this study, researchers examined the effect of a pancreatic enzyme drug on fat absorption.
Study Drugs: PEP Microtabs
Study Ages: >= 7 Years
Type of Therapy: Nutritional-GI Therapies
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Exist
 
81. Safety and Efficacy of Eurand PEP Microtabs in Pediatric Patients with CF Pancreatic Insufficiency
This open-label study evaluated the safety and efficacy of Eurand pancreatic enzyme product (PEP) microtabs in pediatric patients under age 7 with Cystic Fibrosis and Exocrine Pancreatic Insufficiency.
Study Drugs: PEP Microtabs
Study Ages: 1 Days - 6 Years
Type of Therapy: Nutritional-GI Therapies
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Exist
 
82. Use of Utrase MT 12 Enzymes in Young Children with CF Related Pancreatic Insufficiency
This study will look at how effective Ultrase MT 12 can minimize excess fat in the bowel movements of children with CF ages 2- 6 years
Study Drugs: Ultrase MT12
Study Ages: 2 Years - 6 Years
Type of Therapy: Nutritional-GI Therapies
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
83. Phase 3 Study of the Safety and Effectiveness of ULTRASE MT20 for Pancreatic Insufficiency
This study will assess the safety and efficacy of a pancreatic enzyme capsule designed for the absorption of nutrients in patients with CF.
Study Drugs: Ultrase MT20
Study Ages: >= 7 Years
Type of Therapy: Nutritional-GI Therapies
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Exist
 
84. Efficacy and Safety of Ultrase MT20 in Children with CF and Pancreatic Insufficiency
This study is being conducted to demonstrate the efficacy and safety of ULTRASE MT20 in children with CF and pancreatic insufficiency, following the new FDA guidelines.
Study Drugs: Ultrase MT20
Study Ages: 7 Years - 11 Years
Type of Therapy: Nutritional-GI Therapies
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
85. ALTU-135 for the Treatment of CF Exocrine Pancreatic Insufficiency
Researchers evaluated people with CF taking ALTU-135, an oral enzyme replacement therapy, for safety concerns during a period of one year.
Study Drugs: Liprotamase
Study Ages: >= 7 Years
Type of Therapy: Nutritional-GI Therapies
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Exist
 
86. Efficacy and Safety of ALTU-135 in Patients with CF Related Exocrine Pancreatic Insufficiency (DIGEST E)
This study examined if people with CF taking ALTU-135, an oral enzyme replacement therapy, would achieve statistically significant improvements in the absorption of fat when compared to people not taking the enzyme.
Study Drugs: Liprotamase
Study Ages: >= 7 Years
Type of Therapy: Nutritional-GI Therapies
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Exist
 
87. Study of N6022in People with CF who have two copies of the F508del-CFTR mutation
This trial will look at the safety, tolerability and pharmacokinetics and effects CFTR biomarkers of N6022 injected once daily for 7 days in people with CF who are 18 years and older and have two copies of the F508del-CFTR mutation.
Study Drugs: N6022 (N30)
Study Ages: >= 18 Years
Type of Therapy: Other
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 40 Percent Predicted
Trial Results Not Yet Available
 
88. Tiotropium Bromide (Spiriva) Safety and Effectiveness in People with Cystic Fibrosis
This study will look at the safety and effectivesness of tiotropium bromide (Spiriva) inhaled once a day using the Respimat device in people with Cystic Fibrosis.
Study Drugs: Tiotropium Bromide
Study Ages: >= 1 Days
Type of Therapy: Other
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 26 Percent Predicted
Trial Results Not Yet Available
 
89. Effect of Tiotropium Bromide (Spiriva) in People with CF
This study looked at the effects of tiotropium bromide inhaled once a day using the Respimat device.
Study Drugs: Tiotropium Bromide
Study Ages: >= 5 Years
Type of Therapy: Other
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 25 Percent Predicted
Trial Results Exist
 
90. Effect of Proton Pump Inhibitors on CF Exacerbations
This study will determine whether treatment of GERD affects frequency of respiratory exacerbations in CF.
Study Drugs: Esomeprazole Magnesium
Study Ages: >= 18 Years
Type of Therapy: Other
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
91. Effect of Insulin or Repaglinide on Body Weight and Pulmonary Function in Patients with CF Related Diabetes
The study is being conducted to determine whether treatment with either insulin or Repaglinide (a medication that increases insulin levels) will improve healthy body weight and pulmonary function in cystic fibrosis patients who have CF-related diabetes.
Study Drugs: Repaglinide
Study Ages: >= 16 Years
Type of Therapy: Other
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Exist
 
92. Denufosol in People with CF ages 2 - 4 years
The purpose of this study was to look at the safety and tolerability of denufosol aerosolized three times a day in pediatric CF patients 2 to 4 years of age.
Study Drugs: Denufosol
Study Ages: 2 Years - 4 Years
Type of Therapy: Restore Airway Surface Liquid
Pseudomonas Status: Not applicable
B Cepacia Status: Negative
FEV1% Status: >= 1 Percent Predicted
Trial Results Exist
 
93. Denufosol Inhalation Solution in People With Mild CF Lung Disease (TIGER 2)
The purpose of this trial was to evaluate the safety and effectiveness of inhaled Denufosol designed to enhance the hydration and clearance of mucus in the lungs of people with CF.
Study Drugs: Denufosol
Study Ages: >= 5 Years
Type of Therapy: Restore Airway Surface Liquid
Pseudomonas Status: Not applicable
B Cepacia Status: Negative
FEV1% Status: 75 - 110 Percent Predicted
Trial Results Exist
 
94. Denufosol (TIGER 2) Open Label Follow On
This open-label follow on study to TIGER 2 will be evaluating the long term safety of Denufosol in patients with CF. Only enrolling participants by invitation.
Study Drugs: Denufosol
Study Ages: >= 5 Years
Type of Therapy: Restore Airway Surface Liquid
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
95. Denufosol Inhalation Solution for People with CF and Mild Lung Disease (TIGER 1)
The purpose of this trial was to evaluate the safety and effectiveness of inhaled Denufosol designed to enhance the hydration and clearance of mucus in the lungs of CF patients.
Study Drugs: Denufosol
Study Ages: 5 Years - 999 Years
Type of Therapy: Restore Airway Surface Liquid
Pseudomonas Status: Not applicable
B Cepacia Status: Negative
FEV1% Status: >= 75 Percent Predicted
Trial Results Exist
 
96. Inhaled Dry Powder Mannitol in Cystic Fibrosis
This study looked at how safe and how well treatment with inhaled dry powder mannitol worked to clear mucus in the lungs and improve lung function of people with cystic fibrosis.
Study Drugs: Bronchitol
Study Ages: >= 6 Years
Type of Therapy: Restore Airway Surface Liquid
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: 30 - 89 Percent Predicted
Trial Results Exist
 
97. Infant Study of Inhaled Saline (ISIS)
The purpose of this study was to determine whether 7% hypertonic saline (HS) was an effective and safe therapy in infants with CF. Note this study included infants 4 months to 59 months at the enrollment visit. If participated in the Infant Pulmonary Function testing (selected sites), age 4 months to < 16 months at Enrollment visit.
Study Drugs: Hypertonic Saline
Study Ages: 4 Months - 5 Years
Type of Therapy: Restore Airway Surface Liquid
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Exist
 
98. Pilot Safety Study of Inhaled 7% Hypertonic Saline in Infants with CF
This safety study evaluated the tolerability of hypertonic saline given to infants for up to 14 days.
Study Drugs: Hypertonic Saline
Study Ages: 12 Months - 30 Months
Type of Therapy: Restore Airway Surface Liquid
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Exist
 
99. Vestibular and Auditory Sensory Loss in People with CF
This study will include patients with CF who are starting a course of IV Tobramycin for a lung infection in order to test inner ear function during the treatment.
Study Drugs: Tobramycin (IV)
Study Ages: >= 10 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
100. Treatment of early Pseudomonas Aeruginosa
This study will look at the effects of treatment with intravenous antibiotics compared to inhaled tobramycin in clearing mucoid Pseudomonas aeruginosa and reducing inflammation in the airways.
Study Drugs: TOBI
Study Ages: 6 Months - 16 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
101. Early Intervention in Pulmonary Exacerbation in Cystic Fibrosis
This study will compare routine care for a pulmonary exacerbation to a program of early identification and treatment of pulmonary exacerbation in adults with CF.
Study Drugs: Multiple systemic antibiotics
Study Ages: >= 18 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Negative
FEV1% Status: >= 25 Percent Predicted
Trial Results Not Yet Available
 
102. The Effect of Azithromycin on TGF-b1
This study will examine if TGF-b1, a gene responsible for regulation of immune function and tissue repair, is reduced when taking Azithromycin.
Study Drugs: Azithromycin
Study Ages: >= 8 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 40 Percent Predicted
Trial Results Not Yet Available
 
103. Sildenafil in CF lung disease
This single center trial will look at the effect of Sildenafil (Revatio®), a drug already used in other types of lung disease, on symptoms related to lung inflammation and infection in people with CF who are 12 years of age and older.
Study Drugs: Sildenafil
Study Ages: >= 12 Years
Type of Therapy: Anti-Inflammatory
Pseudomonas Status: Not applicable
B Cepacia Status: Negative
FEV1% Status: >= 40 Percent Predicted
Trial Results Not Yet Available
 
104. Pioglitizone for the Treatment of CF Lung Disease
Researchers studied whether a drug called pioglitazone could decrease inflammation in cystic fibrosis lung disease.
Study Drugs: Pioglitazone
Study Ages: >= 18 Years
Type of Therapy: Anti-Inflammatory
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 40 Percent Predicted
Trial Results Exist
 
105. Low-Dose Methotrexate for the Treatment of CF Lung Disease
Researchers studied whether a drug called methotrexate could decrease iflammation in cystic fibrosis lung disease.
Study Drugs: Methotrexate
Study Ages: >= 14 Years
Type of Therapy: Anti-Inflammatory
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 40 Percent Predicted
Trial Results Exist
 
106. Hydroxychloroquine for the Treatment of CF Lung Disease
Researchers studied whether a drug called hydroxychloroquine could decrease inflammation in cystic fibrosis lung disease.
Study Drugs: Hydroxychloroquine
Study Ages: 16 Years - 65 Years
Type of Therapy: Anti-Inflammatory
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 40 Percent Predicted
Trial Results Exist
 
107. Effect of Sulforaphane in Broccoli Sprouts on Nrf2 activation
This single center study looked at whether sulforaphane released from well chewed broccoli sprouts activates Nrf2 in the cells of people with CF who are between the ages of 18 to 49 years.
Study Ages: 18 Years - 49 Years
Type of Therapy: Nutritional-GI Therapies
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Exist
 
108. Alendronate in adults with CF related osteoporosis
This study will look at the bioavailability and biologic effect of alendronate on bone metabolism in people with cystic fibrosis and assess the safety and effectiveness of the study treatment regimen in improving osteoporosis in people with CF.
Study Ages: >= 18 Years
Type of Therapy: Nutritional-GI Therapies
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: 20 - 90 Percent Predicted
Trial Results Not Yet Available
 
109. Pilot Study of Zinc Supplementation in Children with CF
This study will examine the level of zinc absorption, excretion, and balance in children with cystic fibrosis. Researchers would like to find out if children with CF who are given zinc supplements will have a higher zinc balance than CF children who do not take these supplements.
Study Drugs: Zinc
Study Ages: 8 Years - 14 Years
Type of Therapy: Nutritional-GI Therapies
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
110. Acid Suppression therapy in People with CF
This study will look at whether bacteria in the throat changes when people with CF take acid suppression medications, proton pump inhibitors (PPI).
Study Drugs: Proton Pump Inhibitor/PPI
Study Ages: 3 Months - 21 Years
Type of Therapy: Other
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
111. Cystic Fibrosis Nutritional Education and Behavioral Training
This study will look at the effectiveness of a behavioral and nutritional treatment to improve BMI and lung functioning in children with cystic fibrosis ages 3 to 6 years old.
Study Ages: 3 Years - 12 Years
Type of Therapy: Other
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
112. Surfactant Aerosol Pilot Study
This study will looked at whether inhaled aerosol drugs used to treat CF might work better if special chemicals called surfactants, were added to them.
Study Ages: >= 18 Years
Type of Therapy: Other
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 65 Percent Predicted
Trial Results Exist
 
113. Surfactant and Hypertonic Saline
This study will look at the ability of inhaled surfactant to lessen the obstruction of CF airways and to improve mucus clearance. The study will also compare the effect of surfactant treatment to surfactant plus hypertonic saline treatment.
Study Drugs: Hypertonic Saline
Study Ages: >= 14 Years
Type of Therapy: Restore Airway Surface Liquid
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 40 Percent Predicted
Trial Results Not Yet Available
 
114. Hypertonic Saline in Infants and Young Children with Cystic Fibrosis (Pilot)
This single center pilot study assessed the safety of Hypertonic Saline (HS) infants and young children with CF.
Study Drugs: Hypertonic Saline
Study Ages: 1 Months - 8 Years
Type of Therapy: Restore Airway Surface Liquid
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 60 Percent Predicted
Trial Results Exist
 
Recruitment Status: Not Yet Recruiting
1. Staphylococcus (Staph) aureus small-colony variants (SCVs)
This trial will look at how often the germs Staphylococcus (Staph) aureus small-colony variants (SCVs) occur and how they affect lung function. This study is in children ages 6 to 16with cystic fibrosis.
Study Ages: 6 Years - 16 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= Percent Predicted
Trial Results Not Yet Available
 
Recruitment Status: Recruiting
2. GOAL-e2 Expansion Study
This is a prospective, multi-center observational study. The study will look at samples from people with cystic fibrosis who have the R117H and other non-G551D gating CFTR mutations, many of whom are expected to be prescribed ivacaftor during the course of the study. This study is for ages 6 and above.
Study Ages: >= 6 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= Percent Predicted
Trial Results Not Yet Available
 
3. An Ocular Safety Study of Kalyedeco-Treated Children 11 Years of Age or Younger with CF
This trial is designed to evaluate the risk of cataracts (lens opacities) and describe the best corrected distance vision (with glasses/contacts for those who wear them) of children with Cystic Fibrosis who are 11 years of age or younger at the time of ivacaftor (Kalydeco) treatment initiation and are receiving or planning to receive commercially-available ivacaftor (Kalydeco) in the US.
Study Ages: 6 Years - 11 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
4. Porcine Viral Antibody Point Prevalence Study in People with CF Taking Pancreatic Enzymes
This is a point prevalence study conducted entirely in the United States (US) to establish the prevalence of antibodies to hepatitis E virus (HEV) and other selected porcine viruses in people with cystic fibrosis (CF) receiving pancreatic enzyme replacement therapy (PERT) for pancreatic insufficiency compared with matched (age and region of residence) control patients unexposed to PERT.
Study Ages: >= 2 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
5. Fibrosing Colonopathy in Cystic Fibrosis
This is a long-term study to assess the occurrence and risk factors for a rare bowel disorder called fibrosing colonopathy (narrowing of the large intestine) in people with cystic fibrosis who take pancreatic enzymes and are participating in the Cystic Fibrosis Patient Registry.
Study Ages: >= 1 Days
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
6. Sweat Testing in CF Newborns
The purpose of this study is to evaluate the sweat testing results of newborns and their fluid and salt balance. This study is being conducted because it is known that fluid and salt balance may affect sweat testing but this has not been fully determined in babies.
Study Ages: 2 Weeks - 16 Weeks
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
7. Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
This study will look at whether using abdominal ultrasounds predicts the progression of liver disease in children with CF.
Study Ages: 3 Years - 12 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
8. Genetic Modifiers of Cystic Fibrosis: Sibling Study
The purpose of the study is to find genetic and environmental factors affecting the variability in CF.
Study Ages: >= 1 Days
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
9. Genetic Modifiers of Cystic Fibrosis Liver Disease
This study examines â??modifier genesâ?? that may play a role in the development of CF liver disease.
Study Ages: >= 1 Days
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
10. Biomarkers and Exacerbations in CF
This is a single center observational study to determine if biomarkers can be used to identify individuals who would benefit from antibiotic therapy in people with CF ages 14 and older.
Study Ages: >= 14 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Negative
FEV1% Status: >= 25 Percent Predicted
Trial Results Not Yet Available
 
11. Lung Disease in Infants with CF
This study will seek to identify what factors impact lung function in infants with CF.
Study Ages: 1 Years - 3 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
12. A Novel Test to Measure Response to Treatment of a CF Pulmonary Exacerbation
To see whether a novel blood test measuring white blood cell proteins can measure a change in inflammation of lungs after therapy for an exacerbation.
Study Ages: >= 18 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Not applicable
B Cepacia Status: Negative
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
13. Ivacaftor Effects Upon Insulin and Incretin in CF
This is a single center observational study to understand the effect of ivacaftor on blood sugar and insulin in people with CF ages 6 years and older.
Study Ages: >= 6 Years
Type of Therapy: Other
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
Recruitment Status: Recruiting Completed
14. Study to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa in People with CF
This is a 5-year study that enrolled over 500 subjects from the existing Cystic Fibrosis Foundation (CFF) patient registry. Eligible subjects were patients who received care at CFF-accredited centers nationwide. Each enrolled subject provided samples for microbiological evaluation, obtained upon enrollment and then once per year thereafter for 5 years.
Study Ages: >= 1 Years
Pseudomonas Status: Positive
B Cepacia Status: Not applicable
FEV1% Status: 1 - 90 Percent Predicted
Trial Results Not Yet Available
 
15. BONUS - Baby Observational and Nutrition Study
A multi-center observational study following the growth of infants with CF for a duration of 12 months. Data such as length, weight, blood, urine will be collected at routine clinical care visits. This study will help gain a better understanding of the factors that interfere with good growth in infants with CF.
Study Ages: 1 Days - 15 Weeks
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
Recruitment Status: Trial Completed
16. Observational Study in People with CF with the G551D mutation
This was a multi-center observational trial collecting clinical information such as height and weight as well as specimens such as blood and urine in people with CF who have the G551D mutation.
Study Ages: >= 6 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Exist
 
17. Standardization of Mucociliary Clearance Methodology
Comparing the measurement techniques for mucociliary clearance across 3 CF care centers.
Study Ages: 18 Years - 40 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 50 Percent Predicted
Trial Results Not Yet Available
 
18. Assessing Quality of Life in CF After Lung Transplant
This study will compare the quality of life perceptions in children with CF who receive a lung transplant versus those children with CF who are not lung transplant candidates.
Study Ages: >= 6 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status:
Trial Results Not Yet Available
 
19. Characterization of MRSA infection/colonization in CF
This study seeks to define if sub-types of MRSA differ in regards to effect on exacerbations, lung function and nutrition. The study also tests which antibiotics would be most useful for treating MRSA and if children and their parents would need to also have disinfection of nose and skin to avoid re-infection.
Study Ages: 1 Years - 18 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
20. Five Year Extension Study to Evaluate Risk Factors for and Inpact of P. aeruginosa Acquisition
This study is a five year extension study to continue to evaluate the impact of P. aeruginosa acquistion on clinical outcomes in Cystic Fibrosis. Enrollment is limited to patients who completed the original study.
Study Ages: 1 Days - 12 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
21. Longitudinal Assessment of Risk Factors for and Impact of Pseudomonas aeruginosa and Early Anti-Pseudomonal Treatment in Children with CF
This observational study was to learn what may lead to lung infections caused by Pseudomonas aeruginosa (Pa) in children with CF.
Study Ages: 1 Days - 12 Years
Pseudomonas Status: Negative
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Exist
 
22. Detection of Airway CFTR
Develop new biomarkers for the detection of CFTR activity in the airway of CF patients.
Study Ages: >= 8 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
23. Depression and Anxiety in CF Patients and Caregivers
This study will look at depression and anxiety in patients with CF and parent caregivers. Depression and anxiety may have an effect on health outcomes such as change in FEV1, BMI, and number of exacerbations and hospitalizations.
Study Ages: >= 1 Days
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
24. Antimicrobial Resistance in CF
This study enrolled people with CF and compared their sputum microbiology and susceptibility data with data obtained years ago from tobramycin clinical trials. The comparisons between current and previous infections help scientists to determine if use of certain antibiotics has contributed to antibiotic resistance.
Study Ages: >= 6 Years
Pseudomonas Status: Positive
B Cepacia Status: Negative
FEV1% Status: 25 - 75 Percent Predicted
Trial Results Exist
 
25. iCARE study (I Change Adherence and Raise Expectations Study)
The iCARE study is learning which tools and strategies help cystic fibrosis (CF) care teams communicate better with their patients and improve their patientsâ?? CF management.
Study Ages: 11 Years - 20 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
26. Management of Bacterial Air Contamination in CF Clinics
The main purpose of this study is to see whether mask use by CF patients during office visits can reduce contamination of examination room air.
Study Ages: >= 6 Years
Type of Therapy: Other
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
27. Transition Readiness Assessment in CF
This study will compare two health care transition questionnaires to gain knowledge about factors to consider when determining transfer of care from a pediatric to adult CF care program.
Study Ages: 14 Years - 22 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
28. Impaired Glucose Tolerance in People with Cystic Fibrosis
This study will look at identifying the frequency of diagnosing cystic fibrosis related diabetes (CFRD)and impaired glucose tolerance (IGT) using oral glucose tolerance test screening (OGTT).
Study Ages: 8 Years - 25 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
29. Infants Exhaled Breath Condensate
This study sought to determine if the use of the non-invasive technique, exhaled breath condensate (EBC), could detect airway inflammation in infants lungs.
Study Ages: 5 Months - 35 Months
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Exist
 
30. Immune Responses and Pulmonary Phenotype
This study will look at variation in specific immune responses among individuals with identical CFTR genotypes.
Study Ages: >= 18 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
31. SCN Secretion in CF
This study will seek to identify a defect in the airway fluid of patients with CF.
Study Ages: >= 18 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 70 Percent Predicted
Trial Results Not Yet Available
 
32. Pseudomonas Aeruginosa Infections by ELISA Testing
This study will look at developing a test to detect antibodies against Pseudomonas aeruginosa in the saliva of young children with CF.
Study Ages: 1 Months - 16 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
33. Neutrophils in CF Exacerbation
This study will look at changes in neutrophils during a CF exacerbation.
Study Ages: >= 7 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
34. Inflammation and Oxidant Stress in Cystic Fibrosis Related Diabetes
This study will look at oxidant and inflammatory effects in the development of Cystic Fibrosis Related Diabetes.
Study Ages: >= 18 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
35. Early Staphylcoccal and Other Bacterial Infections in CF
This study will look at what bacteria in the airway of young children grows from oropharyngeal swab samples. It will also look to see if S. Aureus, P. aeruginosa and anaerobic bacteria effect airway disease progression.
Study Ages: 1 Days - 4 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
36. Biomarkers of Lung Injury in CF Children
The purpose of the study is to learn if a urine and sputum test can be used to measure if lung damage occurs over a long period of time (two years) or when patients are sick.
Study Ages: 8 Years - 25 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 35 Percent Predicted
Trial Results Not Yet Available
 
37. Biomarkers in Breath Condensate in Children with CF
This study will look at exhaled breath condensate as a measurement of airway inflammatory biomarkers.
Study Ages: 6 Years - 21 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
38. Anaerobic Bacteria in CF
The goal of the project is to understand how each germ found in the lungs of CF patients is involved in disease and the best way to treat lung infections in CF.
Study Ages: >= 6 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
International Only
1. Arikace Compared to TOBI in People with CF with Chronic Pseudomonas Aeruginosa Infections
This trial will look at whether Arikace is effective in treating chronic lung infections caused by Pseudomonas aeruginosa in people with Cystic Fibrosis. The effectiveness, safety and tolerability of Arikace will be compared to TOBI, an inhalation antibiotic already available for use.
Study Drugs: Arikace
Study Ages: >= 6 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Not applicable
FEV1% Status: >= 25 Percent Predicted
Trial Results Not Yet Available
 
2. Azithromycin Infant Study
This study will look at the safety and effectiveness of 3 years of treatment with azithromycin compared to placebo in infants with CF.
Study Drugs: Azithromycin
Study Ages: 3 Months -
Type of Therapy: Anti-Infective
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status:
Trial Results Not Yet Available
 
3. Probiotic Use in People with Cystic Fibrosis
This study will look at the effect of probiotic use for 1 year in children with CF.
Study Drugs: Lactobacillus rhamnosus GG
Study Ages: 2 Years - 16 Years
Type of Therapy: Nutritional-GI Therapies
Pseudomonas Status: Not applicable
B Cepacia Status: Negative
FEV1% Status: >= 50 Percent Predicted
Trial Results Not Yet Available
 
4. Prevention of Chronic Pseudomonas Infection
This study will look at the effectiveness of two different medication treatment plans in preventing chronic pseudomonas aeruginosa lung infections.
Study Drugs: Ciprofloxacin (oral)
Study Ages: >= 1 Months
Type of Therapy: Anti-Infective
Pseudomonas Status: Positive
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
5. Effect of Azithromycin in People with CF and B. Cepacia
This study will examine the effectiveness of azithromycin in improving the lung function in people with CF infected with the bacteria Burkholderia cepacia complex.
Study Drugs: Azithromycin
Study Ages: >= 19 Years
Type of Therapy: Anti-Infective
Pseudomonas Status: Not applicable
B Cepacia Status: Positive
FEV1% Status: >= 30 Percent Predicted
Trial Results Not Yet Available
 
6. Inhaled Glutathione in People with CF
This study will look at the tolerability and effect of inhaled gluthathione on FEV1 in people with CF.
Study Drugs: Glutathione (Inhaled)
Study Ages: >= 8 Years
Type of Therapy: Anti-Inflammatory
Pseudomonas Status: Not applicable
B Cepacia Status: Negative
FEV1% Status: 40 - 90 Percent Predicted
Trial Results Not Yet Available
 
7. Glutamine Supplementation for Cystic Fibrosis
This study willevaluate the safety and tolerability of aerolized glutathione compared with normal saline. The main outcome measure is pulmonary function testing (PFT)
Study Drugs: Glutamine
Study Ages: >= 14 Years
Type of Therapy: Anti-Inflammatory
Pseudomonas Status: Positive
B Cepacia Status: Not applicable
FEV1% Status: >= 40 Percent Predicted
Trial Results Not Yet Available
 
8. Choline Supplementation in Children with CF
This research will look to find out if choline supplements over a longer duration of 6 months will improve and maintain normal choline status in children.
Study Drugs: Choline
Study Ages: 5 Years - 17 Years
Type of Therapy: Anti-Inflammatory
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
9. Early Predictors of Lung Disease
This study will look at different factors that affect lung function in infants. Infants will be followed until 4 years of age.
Study Ages: 14 Days - 4 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available
 
10. Breath Glucose Biomarker
This study will find out how useful breath glucose is as a measure of CF lung disease.
Study Ages: >= 18 Years
Pseudomonas Status: Not applicable
B Cepacia Status: Not applicable
FEV1% Status: >= 1 Percent Predicted
Trial Results Not Yet Available